Posted by Michael Wonder on 28 Feb 2026
Highlights from the 23-26 February 2026 CHMP meeting
27 February 2026 - The EMA’s CHMP has recommended 12 medicines for approval at its February 2026 meeting.
The committee recommended granting a marketing authorisation for mCombriax (influenza and COVID-19 mRNA vaccine), the first combined messenger RNA vaccine for protecting people aged 50 years and older against COVID-19 and seasonal influenza.
